Leadership Reloaded: Marksans Pharma Renews Mark Saldanha’s Command for Global Edge

Marksans Pharma Ltd board has re-elected Mr. Mark Saldanha as Managing Director for five years from October 6, 2025, by a unanimous board decision. This top-level decision is an indication of the board's confidence in Saldanha's leadership as Marksans aims to achieve increased international reach and innovation in the pharma domain.

Key Highlights
Five-Year Term: Mark Saldanha continues as Managing Director for an additional five-year term from October 6, 2025, bringing about continuity of leadership and strategy.

Board Approval: The decision follows a period of sustained company growth, robust financial performance, and Saldanha's role as chief architect to the company's global success.

Declaration of Dividend: The board also fixed a meeting on August 12, 2025, to consider for approval Q1 FY26 results and to declare a dividend to the shareholders, the record date whereof shall be August 1, 2025.

Recent Achievements: During Saldanha's leadership, Marksans Pharma has achieved all-time high revenue of ₹2,623Cr in FY25 and outstanding growth in the US market.

Leadership Repositioning: The company has recently undergone restructuring of its independent directorship, with SR Buddharaju having completed his tenure in March 2025.

Why It Matters
Mark Saldanha's leadership vision has been noted for transforming Marksans Pharma into a global pharma player through continued investments in research, market expansion, and operational excellence. The reappointment signposts stability and clear direction of strategy to stakeholders. 

Source: MarketScreener, Moneycontrol, Screener, Economic Times, Business Standard